Open AccessTreatment of hereditary angioedema with plasma-derived C1 inhibitor
Author(s) -
Timothy Craig
Publication year - 2008
Publication title -
therapeutics and clinical risk management
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.719
H-Index - 55
eISSN - 1178-203X
pISSN - 1176-6336
DOI - 10.2147/tcrm.s3172
Subject(s) - hereditary angioedema , medicine , c1 inhibitor , angioedema , dermatology , english language , placebo , intensive care medicine , pharmacology , pathology , alternative medicine , philosophy , linguistics
Plasma-derived C1 inhibitor (C1-INH) concentrate is a treatment option for acute hereditary angioedema (HAE) attacks and is considered the standard-of-care in many countries, although it is not yet available in the United States. Studies are still being conducted to establish its safety and efficacy as required by the FDA.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom